慢性乙型肝炎伴肝胆结石病人胆汁、外周静脉血、门静脉血中HBsAg和HBV-DNA的存在探讨

对29例慢性乙型肝炎伴肝胆结石患者.采用Elisa和斑点杂交技术检测外周静脉血、胆管胆汁和门静脉血中乙型肝炎两对半及HBV-DNA.并比较HkAg含量.结果，外周静脉血、胆汁和门静脉血中HBsAg浓度分别为;2244.73±59722ng／ml、1181.65±370.91ng／ml、2013.62±483.47ng／ml;HBV-DNA阳性检出率分别为62.07％（18例），72.41％（21例）及68.97％（20例）.提示肝细胞内复制的HHV在进入血循环的同时，部分随胆汁的分泌排入肠道，并可能通过受损肠粘膜进入门静脉再回到肝脏，造成HBV对肝脏的重复感染。     

血清Ⅲ型原胶原含量与肝纤维化的关系（附102例肝活检分析）

为进一步研究血清Ⅲ型原胶原（ＰＣⅢ）含量与肝纤维化的关系，对肝炎患者血清ＰＣⅢ含量与肝炎组织学变化进行对比分析．方法：用ＲＩＡ法测定６１６例急、慢性肝炎及肝硬化患者的血清ＰＣⅢ含量，其中１０２例同时做肝活检，按照Ｋｎｏｄｅｌｌ肝组织炎症活动性指数标准记分．结果：急、慢性肝炎及肝硬化患者血清ＰＣⅢ含量明显高于正常人，差异有显著性（Ｐ＜ｏ．０５～０．０１）．其升高的血清ＰＣⅢ含量与肝细胞坏死范围及门管区炎症程度无相关性（ｒ＝０．４９４，Ｐ＞０．０５），而与肝纤维化程度呈正相关（ｒ＝０．６６８，Ｐ＜０．０１）．结论：血清ＰＣⅢ测定是判断慢性肝炎及肝硬化时肝纤维化程度的有用指标．     

Papillitis and vasculitis of the arteria spinalis anterior as complications of hepatitis C reinfection after liver transplantation

It is well known that hepatitis C virus (HCV)-related chronic liver disease may be associated with various immunological disorders including mixed cryoglobulinemia, which is accompanied by cutaneous vasculitis, arthralgias, membranoproliferative glomerulonephritis, and neuropathy in association with cryoprecipitable immune complexes in serum. We describe here the first case of central nervous system HCV infection with evidence of the virus in the cerebrospinal fluid in association with cryoglobulinemia in a patient who developed recurrent episodes of papillitis and vasculitis of the arteria spinalis anterior after liver transplantation. Received: 3 September 1996 Received after revision: 13 November 1996 Accepted: 6 December 1996     

新生儿先天性畸形与孕妇乙型肝炎病毒感染关系的研究

为探讨孕妇乙型肝炎病毒(HBV)感染和某些因素对先天性畸形的致病作用,本文进行了96对新生儿先天畸形的配对(1:1)病例对照研究,报道先天畸形的频率和构成,单因素和多因素的条件Logistic回归分析,表明孕妇HBsAg阳性等6个因素对先天畸形呈阴性结果,而与接触农药和孕周的因素有明显联系,值得进一步探讨。     

抗—HCV阳性单采浆供血员HGV感染随访研究

为了解单采浆供血员庚型肝炎病毒（ＨＧＶ）感染及其转归，对１０２名抗－ＨＣＶ阳性单采浆供血员冻存血清进行抗－ＨＧＶ和ＨＧＶＲＮＡ检测，对抗－ＨＧＶ和（或）ＨＧＶＲＮＡ阳性者作３年随访研究。采用ＥＩＡ法检测抗－ＨＧＶ，包被抗原来自ＨＧＶ不同功能区的合成肽。应用ＲＴ－ＰＣＲ法检测ＨＧＶＲＮＡ，引物选自ＨＧＶＮＳ３区。结果表明，抗－ＨＣＶ阳性单采浆供血员ＨＧＶＲＮＡ阳性率为１９．６１％（２０／１０２），抗－ＨＧＶ阳性率为１７．６５％（１８／１０２），ＨＧＶ感染率（抗ＨＧＶ和／或ＨＧＶＲＮＡ阳性）为２４．５１％（２５／１０２），而对照组仅为０．９４％（１／１０６）。提示单采血浆是ＨＧＶ感染的重要危险因素。ＨＧＶＲＮＡ和抗－ＨＧＶ的３年阴转率分别为３５．００％（７／２０）和１１．１１％（２／１８），说明ＨＧＶ感染有慢性携带趋势     

大鼠肝细胞Ⅰ，Ⅲ型前胶原基因表达及PDGF的影响

目的观察大鼠肝细胞Ⅰ，Ⅲ型前胶原基因的表达及ＰＤＧＦ对其表达的影响．方法应用原位杂交技术检测分离培养的ＳＤ大鼠肝细胞（ｎ＝３０）内Ⅰ，Ⅲ型前胶原基因的表达．同时观察１０μｇ／Ｌ（ｎ＝３０）和３０μｇ／Ｌ（ｎ＝３０）ＰＤＧＦ促进前胶原基因表达的作用．测定基因表达颗粒总面积占细胞总面积的百分比，并作比较分析．结果无论正常肝细胞或是在两种浓度的ＰＤＧＦ存在时，肝细胞内均可见到Ⅰ，Ⅲ型前胶原基因的表达．正常肝细胞Ⅰ，Ⅲ型前胶原基因表达面积的百分比（％）为７７±１９和７５±２１；加１０μｇ／ＬＰＤＧＦ后为１１５±１９和１１２±１０，而加３０μｇ／Ｌ后为１５２±３４及１８１±２８，且在后者中表达明显增强（Ｐ＜００５及Ｐ＜００１）．结论ＰＤＧＦ在转录水平上促进肝细胞胶原的合成．     

原发性肝癌,肝硬化患者血清中丙肝病毒抗体的检测

应用国产ELISA试剂盒对157例肝癌、肝硬化病人血清中抗-HCV及HBV-M进行检测，101例肝癌10例抗-HCV阳性，阳性率为9．9％；56例肝硬化6例抗-HCV阳性，阳性率为10．7％；肝癌组抗HCV与HBsAg双阳性率79％（8／101），HBsAg阳性率为723％（73／101），明显高于HCV感染率，说明HBV仍是乙肝流行地区的主要相关因素。14例抗-HCV阳性（包括可疑阳性），肝癌外周血中8例（57．1％）HBsAg阳性，推测HCV可单独作用但更常与HBV形成混合感染参与慢性肝病的癌变过程。     

肝硬化组织转化生长因子β1 的分布研究及临床意义

目的研究转化生长因子β1(TGFβ1)、胶原纤维和网状纤维在肝硬化组织中的分布、意义及肝细胞癌变对其分布的影响.方法采用免疫组织化学SP法检测30例肝硬化组织和1例大致正常肝组织TGFβ1的表达情况.用Masson染色显示胶原纤维,Gordon-Sweet染色显示网状纤维.CMIAS-8彩色图像分析系统对阳性目标进行分析处理.结果 (1)TGFβ1主要位于肝非实质细胞胞浆内,这些细胞主要分布在汇管区、纤维间隔、炎症区;纤维组织中有少量TGFβ1存在;少数肝细胞胞浆内也表达TGFβ1,总阳性率为20%,肝炎肝硬化组TGFβ1阳性表达率与肝炎肝硬化合并原发性肝细胞癌组比较无显著性差异(P>0.05);(2)肝炎肝硬化组TGFβ1的IOD为395.3±291.3,胶原纤维的AD为(6.3±3.8)%,网状纤维的AD为(5.4±2.3)%.TGFβ1的IOD与胶原纤维的AD呈正相关(r=0.8991,P<0.01),与网状纤维的AD呈正相关(r=0.8317,P<0.01);肝炎肝硬化合并原发性肝细胞癌组TGFβ1 的IOD为840.7±449.6,胶原纤维的AD为(12.5±4.9)%,网状纤维的AD为(9.2±3.2)%.TGFβ1的IOD与胶原纤维的AD呈正相关(r=0.8025,P<0.01),与网状纤维的AD无相关(r=0.4314,P>0. 05).肝炎肝硬化组TGFβ1的表达、胶原纤维和网状纤维分布与肝炎肝硬化合并原发性肝细胞癌组比较均有显著性差异(P均<0.01);(3)胶原纤维主要分布在汇管区、纤维隔,炎症区,肝窦旁也可见少量存在;网状纤维主要分布在汇管区、纤维隔、炎症区、肝窦旁、实质细胞周围;原发性肝癌及外周肝硬化组织Gordon-Sweet染色显示肝癌细胞区网状纤维不显色.结论 TGFβ1与肝纤维化肝硬化的发生发展密切相关.在肝炎肝硬化,TGFβ1表达增强,当合并原发性肝细胞癌时,TGFβ1有极强表达;TGFβ1可作为原发性肝细胞癌的血清学辅助诊断,Gordon-Sweet染色可作为原发性肝细胞癌的病理学辅助诊断.     

Treatment of hepatitis B and C after liver transplantation. Part 2, hepatitis C

Abstract End-stage liver disease caused by the hepatitis C virus is a major indication for liver transplantation. However, recurrence of hepatitis in the graft is a major issue. HCV re-infection after transplantation is almost constant, and recent data confirm that it significantly impairs patient and graft survival. Factors that may influence disease severity and consequent progression of HCV graft injury remain unclear. Chronic HCV infection develops in 60%–80% of patients, and 6%–28% ultimately progress to cirrhosis within 5 years. Pre-transplantation antiviral treatment is not easily related to poor tolerance. Attempts to administer prophylactic post-transplantation antiviral treatment are under evaluation but are limited by antiviral drug side effects. Treatment of established graft lesions with interferon or ribavirin as single agents has been disappointing. Combination therapy gave promising results, with sustained virological response in 25% of patients, but indications, modality and duration of treatment should be assessed.     

EDTA Registry centre survey, 1986. Report from the European Dialysis and Transplant Association Registry

This paper summarises the information given on the 1986 EDTA Registry centre questionnaire which was returned by 82% of the 2,065 known dialysis and transplant centres in 33 European countries. Information is given on the number of patients alive on haemodialysis according to the type of dialysis facilities available where the patient was receiving dialysis and the number of patients receiving special types of dialysis. The centre questionnaire also included questions on testing for HIV infection, serological evidence or symptoms of AIDS and the diagnosis of hepatitis B in patients and staff. The data given in response to these questions are presented together with data on the involvement of dietitians and social workers in the treatment of patients with end stage renal failure. Finally, information on transplant activity in Europe and the treatment policies of transplanting centres is provided.